Tenaya Therapeutics Inc

Tenaya Therapeutics granted stock options to purchase 1,650,000 shares to newly appointed CFO Eric Hyllengren and an aggregate of 187,200 shares to two new non-executive employees. The options have an exercise price of $0.8365 per share, equal to the July 13, 2026 closing price, a ten-year term, and vest over four years with a one-year cliff and monthly vesting thereafter. The grants were made under the 2024 Inducement Equity Incentive Plan as an inducement material to employment in accordance with NASDAQ Listing Rule 5635(c)(4).

Tenaya Therapeutics has appointed Eric Hyllengren as Chief Financial Officer, effective July 13. Hyllengren most recently served as CFO of Zura Bio and previously held the roles of CFO and Chief Operating Officer at Atara Biotherapeutics. Earlier in his career, he spent 15 years at Amgen in roles of increasing responsibility across finance, investor relations, and business development.